Fig. 3From: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancerCXCR1+ cell evaluation in core biopsy samples by flow cytometry. a All viable cells. b Tumor cells. Symbols represent individual patients. Patient 16’s day 21 core biopsy was taken on the day of surgeryBack to article page